EL PASO, Texas--(BUSINESS WIRE)--Premier Biomedical, Inc. (OTCQB:BIEI), a biotech research public company, and Auramedi Farmacêutica Ltda (a Brazilian pharmaceutical company) announced the signing of a non-binding Letter of Intent (LOI) to enter into discussions to explore forming a possible Joint Venture (JV) in Brazil to develop Premier’s various treatment technologies, and oversee the manufacture and distribution of the drugs and devices in the South American market initially. The formation of this joint venture is expected to expedite the approval, manufacture, sales and distribution of Premier’s proprietary treatments. A third party has projected annual sales, in South America, for Premier’s treatments at $400M by the year 2020.
William A. Hartman, President and CEO of Premier Biomedical, stated: “We are very excited to embark on this relationship with such a dedicated pharmaceutical company as Auramedi. We expect that the resulting JV will be beneficial not only to Premier and Auramedi, but to the patients in Brazil and South America suffering from hard to cure or previously incurable diseases for which we are working very hard to bring effective treatments to market. The Joint Venture will have access to all of Premier’s currently available drugs and treatments, as well as those under development.”
Telesforo Cáceres, Director of Auramedi Farmacêutica, declared: “Auramedi was designed, and created, to operate in segments such as Dermatology, Oncology, rare diseases and other difficult to treat diseases. We are very excited about the future possibilities that this strategic alliance with Premier Biomedical raises. The anticipated Joint Venture meets our goals relative to technology transfer, research and manufacturing of innovative products and treatments in Brazil, and will contribute significantly to saving lives and improving the quality of life for patients in our country and South America. The Joint Venture is expected to allow Auramedi to participate in markets that are estimated in Brazil at around $600 million today, and currently lacking therapeutic innovations.”
About Auramedi Farmacêutica Ltda
Auramedi (http://www.auramedi.com/) is a Brazilian pharmaceutical company, dedicated to bringing to Brazilian prescribers, and consumers, new concepts related to treatments for their health and well-being, based on innovation and growth in each of its products. Auramedi is highly committed to finding solutions and treatments to achieve the best result for patients, prescribers, caregivers, consumers and all those who go through some challenge in their health or well-being, so they may have access to the best medical and pharmaceutical treatments science is able to offer.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI." http://www.premierbiomedical.com/
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.